Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 May 22;123(21):3212-4.
doi: 10.1182/blood-2014-04-565325.

Predicting treatment outcomes in CLL

Adrian Wiestner  1
Affiliations
Comment

Predicting treatment outcomes in CLL

Adrian Wiestner. Blood. .

Abstract

In this issue of Blood, Stilgenbauer and colleagues report on the prognostic and predictive value of gene mutations assessed prospectively in patients with chronic lymphocytic leukemia (CLL) treated with first-line chemoimmunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

None
Interrelationship between NOTCH1 mutations (mut) and other recurrently mutated genes and fluorescence in situ hybridization abnormalities in CLL (A). The length of the arc corresponds to the frequency of the genetic lesion, whereas the width of the ribbon indicates the frequency of cooccurrence with the second marker. Kaplan-Meier estimates of PFS for patients stratified by treatment arm and NOTCH1 mutation status (B). WT, wild-type. Panels taken and slightly modified from Figures 1B and 2A in the article by Stilgenbauer et al that begins on page 3247.
See this image and copyright information in PMC

Comment on

  • Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
    Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H. Stilgenbauer S, et al. Blood. 2014 May 22;123(21):3247-54. doi: 10.1182/blood-2014-01-546150. Epub 2014 Mar 20. Blood. 2014. PMID: 24652989 Clinical Trial.

References

    1. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–3254. - PubMed
    1. Chiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2012;2012:76–87. - PubMed
    1. Niemann CU, Jones J, Wiestner A. Towards targeted therapy of chronic lymphocytic leukemia. Adv Exp Med Biol. 2013;792:259–291. - PubMed
    1. Hallek M, Fischer K, Fingerle-Rowson G, et al. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174. - PubMed
    1. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389–1401. - PMC - PubMed